ZebiAI & Relay Therapeutics Merger: $85M Upfront, $185M Potential
ZebiAI Therapeutics, Inc. and Relay Therapeutics, Inc. (Nasdaq: RLAY) have announced a merger deal. The shop deal, valued at $85 million upfront, is being represented by WilmerHale for ZebiAI, led by Chris Barnstable-Brown, Ariel Soiffer, and Jenna Ventorino. Relay is represented by Wilson Sonsini Goodrich & Rosati.
The merger deal includes an upfront payment of $85 million, consisting of $20 million in cash and $65 million in Relay common stock. Additionally, up to $185 million in contingent payments may be made based on certain milestones and agreements. This shop deal marks a significant step for both companies, with Relay acquiring ZebiAI to strengthen its portfolio and capabilities.
The merger deal, valued at $85 million upfront with potential additional payments, is set to bring together ZebiAI and Relay Therapeutics. The deal is being facilitated by prominent legal firms, with WilmerHale representing ZebiAI and Wilson Sonsini Goodrich & Rosati representing Relay.
Read also:
- C3IC Publishes 'This is the Taiwan We Love' Guide to Empower Citizens
- Reporter of Silenced Torment or Individual Recording Suppressed Agony
- Solar panel troubles on rooftops
- EPA Administrator Zeldin travels to Iowa, reveals fresh EPA DEF guidelines, attends State Fair, commemorates One Big Beautiful Bill
